Pathos AI raises $237 million Series E led by Bristol Myers Squibb at about $3 billion value
The New York drug developer will use the money to grow its Foundry AI platform and move its clinical assets forward.
The 30-second read
- Pathos AI closed a $237 million Series E round led by Bristol Myers Squibb, with existing investors joining.
- The post-money valuation is approximately $3 billion.
- The money will scale the Foundry AI platform and advance four clinical assets, led by JSKN016.
IllustrationPathos AI has closed a Series E round of $237 million. Bristol Myers Squibb led the round, and existing investors also took part. The post-money valuation is approximately $3 billion. The company announced the round on October 23, 2026, according to its own website.
Pathos is a clinical-stage AI and technology company based in New York City, and it develops drugs. CEO Iker Huerga said: "We are building a platform to systematically improve the probability of success in drug development." Huerga earlier worked at Memorial Sloan Kettering, AstraZeneca and Tempus AI.
The funds will go towards Foundry, the company's AI platform, which runs on thousands of AI agents built for specific tasks. Pathos will also push JSKN016 towards registrational studies. It will keep developing pocenbrodib, AZD4241 and DO-2. These are its four active clinical assets.
Pathos obtained the rights to JSKN016 outside Greater China. AZD4241 is partnered with AstraZeneca, and the financial terms were not disclosed.
Why it matters
A large drugmaker leading a round in an AI drug developer shows how pharma is backing this approach. Indian readers following AI and healthcare can watch how such platforms move assets towards late-stage trials.
The data
| Asset | Note |
|---|---|
| JSKN016 | Rights outside Greater China obtained by Pathos; to advance toward registrational studies |
| pocenbrodib | Active clinical asset |
| AZD4241 | Partnered with AstraZeneca; financial terms undisclosed |
| DO-2 | Active clinical asset |
